Breaks Categories: Stock Spotlights

FridayMar 05, 2021 1:52 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Solution Holds Ability to Bridge the Gap in Neuro Testing

Brain Scientific (OTCQB: BRSF) is focused on modernizing brain diagnostics through cutting-edge technologies. The company’s NeuroCap(TM) offers a cost-effective, disposable solution that has the ability to bridge the gap in access to neurological testing. A recent article discussing this reads, “The NeuroCap has clear advantages to its bulkier EEG counterpart. The bulkier version requires a skilled specialist to administer, comes with metal disks and wires, requires constant cleaning and sterilization, and takes up to 30 minutes to administer, not including prep or cleaning time. With the NeuroCap, clinical personnel can apply the disposable headset in five minutes or less. This…

Continue Reading

FridayMar 05, 2021 1:36 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Bringing Effective Solutions to Vast Market

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is engaged in establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company is currently focused on bladder cancer, the most expensive cancer to treat due to a high 50% recurrence rate that leaves approximately 600,000 U.S. patients living in fear that their cancer will return. Imagin Medical’s i/Blue(TM) Imaging System has the ability to overcome limitations of today’s white and blue light cystoscopy procedures. The innovative technology enables surgeons to see real-time white and blue light images on the screen simultaneously during a…

Continue Reading

ThursdayMar 04, 2021 2:23 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leveraging AI, Proprietary Database to Improve Outcomes for Patients of Today and Tomorrow

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. A recent article discussing this reads, “Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is…

Continue Reading

ThursdayMar 04, 2021 2:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues. For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction. VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several…

Continue Reading

WednesdayMar 03, 2021 2:32 pm

BioMedNewsBreaks – RYAH Group Inc. Set to be at Forefront of Data-Driven Medical Future

RYAH Group, a leading digital health care analytics and technology company, is set to benefit with a commitment to advancing the world’s transition to remote-health solutions and data analytics in patient treatments. A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape the field in 2021, reporting that big data management is increasingly necessary with the blossoming use of artificial intelligence (“AI”) and machine learning in health care (https://ibn.fm/ESnrL). RYAH is set to be at the forefront of the information-driven future as a company committed to leveraging the value of health devices combined with data…

Continue Reading

FridayFeb 26, 2021 2:06 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients

Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has…

Continue Reading

ThursdayFeb 25, 2021 3:18 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging(TM) Technology Holds Potential Across Multiple Endoscopic Procedures

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on changing the standards of visualizing cancer during minimally invasive procedures. The company’s innovative technology has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. The state-of-the-art control unit features a dual-wavelength light source, two-channel camera control and data recorder. Simultaneous white and blue light illumination of the bladder allows for side-to-side image monitoring and better visualization of tumors and margins. A recent article discussing…

Continue Reading

TuesdayFeb 23, 2021 3:33 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s App Addresses Treatment Barriers

United Medical Equipment (“UME,” “UMEBSNI”) is focused on providing reliable resources and solutions to help health-care systems work smarter, providers work more proficiently, and patients live healthier lives. Essential to any treatment plan are medication management and collaboration between patient and physician. Two large barriers in medication adherence include poor provider-patient communication and inadequate knowledge about a drug (https://ibn.fm/qzXy6). United Medical has developed a medication management solution to address these barriers: a free app available for download on the Apple App Store and Google Play. A recent article discussing the solution reads, “The free seven-day trial version of the Medication…

Continue Reading

MondayFeb 22, 2021 3:05 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) E-Tattoo Will Be ‘Next Wave of Innovation for Neurology’

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. As scientists work to understand what causes Parkinson’s, Alzheimer’s, dementia and other neurological issues, BRSF is making inroads in helping identify root neurological problems. The company has unveiled a new initiative to develop an innovative e-tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes are designed for connection to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. The solution enables each patient’s data…

Continue Reading

MondayFeb 22, 2021 2:55 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as well as the potential of addressing other central nervous system malignancies. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our…

Continue Reading